Table 3.
Bayesian model-based analysis of deterioration over time following organ preservation compared with UK age-matched general population norm data
| Baseline | 3 months | 6 months | 12 months | 24 months | 36 months | ||
|---|---|---|---|---|---|---|---|
| EORTC-QLQ-C30 core outcomes | |||||||
| Quality of life (global health status) | |||||||
| Randomised patients | 9·1% | 20·0% | 13·5% | 15·4% | 15·7% | 15·0% | |
| Non-randomised patients | 17·2% | 26·0% | 21·8% | 23·4% | 20·3% | 24·1% | |
| Physical functioning | |||||||
| Randomised patients | 18·3% | 27·1% | 29·5% | 28·9% | 33·0% | 30·7% | |
| Non-randomised patients | 26·2% | 40·4% | 37·1% | 37·4% | 37·3% | 41·4% | |
| Role functioning | |||||||
| Randomised patients | 14·6% | 42·8% | 34·5% | 27·2% | 39·8% | 34·4% | |
| Non-randomised patients | 28·0% | 47·5% | 37·4% | 35·6% | 39·2% | 47·5% | |
| Social functioning | |||||||
| Randomised patients | 20·7% | 46·9% | 31·2% | 33·4% | 42·8% | 40·8% | |
| Non-randomised patients | 32·1% | 58·9% | 42·4% | 52·1% | 41·9% | 40·1% | |
| Diarrhoea | |||||||
| Randomised patients | 28·1% | 25·3% | 32·1% | 18·5% | 23·0% | 17·2% | |
| Non-randomised patients | 33·2% | 44·1% | 27·1% | 26·6% | 22·6% | 35·3% | |
| EORTC-QLQ-C30 non-core outcomes | |||||||
| Emotional functioning | |||||||
| Randomised patients | 31·9% | 20·6% | 23·3% | 23·2% | 29·4% | 25·9% | |
| Non-randomised patients | 39·4% | 37·5% | 36·0% | 34·5% | 29·7% | 30·6% | |
| Cognitive functioning | |||||||
| Randomised patients | 39·1% | 39·3% | 36·1% | 41·8% | 38·2% | 29·7% | |
| Non-randomised patients | 51·0% | 53·2% | 53·0% | 52·8% | 53·1% | 60·5% | |
| Fatigue | |||||||
| Randomised patients | 24·9% | 30·5% | 33·8% | 26·7% | 31·4% | 32·0% | |
| Non-randomised patients | 31·5% | 49·7% | 40·3% | 41·4% | 39·4% | 44·4% | |
| Nausea and vomiting | |||||||
| Randomised patients | 10·0% | 6·1% | 11·1% | 21·0% | 16·6% | 10·0% | |
| Non-randomised patients | 16·6% | 18·8% | 12·7% | 13·2% | 16·8% | 14·4% | |
| Pain | |||||||
| Randomised patients | 21·8% | 19·5% | 34·3% | 20·3% | 26·4% | 27·0% | |
| Non-randomised patients | 20·4% | 25·8% | 24·5% | 24·8% | 23·9% | 33·1% | |
| Dyspnoea | |||||||
| Randomised patients | 20·7% | 16·5% | 41·4% | 39·5% | 29·2% | 33·0% | |
| Non-randomised patients | 25·9% | 34·8% | 23·5% | 29·1% | 32·7% | 39·4% | |
| Insomnia | |||||||
| Randomised patients | 44·3% | 52·1% | 53·4% | 52·3% | 40·8% | 42·2% | |
| Non-randomised patients | 54·8% | 60·2% | 55·2% | 54·0% | 60·4% | 51·6% | |
| Appetite loss | |||||||
| Randomised patients | 14·7% | 14·3% | 16·8% | 6·2% | 23·6% | 13·4% | |
| Non-randomised patients | 18·5% | 29·6% | 20·8% | 21·2% | 22·2% | 23·0% | |
| Constipation | |||||||
| Randomised patients | 0·4% | 6·2% | 10·4% | 9·9% | 23·2% | 20·4% | |
| Non-randomised patients | 34·0% | 31·8% | 39·5% | 28·6% | 41·4% | 23·7% | |
| Financial difficulties | |||||||
| Randomised patients | 4·6% | 6·8% | 14·1% | 6·9% | 22·7% | 0·6% | |
| Non-randomised patients | 12·4% | 19·5% | 10·1% | 16·6% | 14·9% | 8·4% | |
| EQ-5D-3L | |||||||
| Index value | |||||||
| Randomised patients | 1·4% | 0·7% | 15·8% | 1·3% | 18·5% | 7·7% | |
| Non-randomised patients | 8·2% | 30·4% | 5·4% | 17·5% | 9·0% | 81·4% | |
EORTC=European Organisation for Research and Treatment of Cancer. QLQ=quality of life. C30=core module. EQ-5D-3L=EuroQol-5 Dimensions-3 Level.